Latest Headlines

Latest Headlines

Indian drugmakers take page from HIV playbook for hep C combo pill

Indian drug manufacturers are working to combine drugs used to treat hepatitis C in ways not possible in the West because of patent restrictions, according to a Bloomberg News report.

India's GVK apparently lost its quality reputation to love, report says

An extramarital affair has cost GVK Biosciences millions of dollars in lost opportunity and brought unwanted scrutiny of its testing procedures and a ban on the marketing of about 700 generic drugs tested at a facility where the affair began, according to a report in The Hindu newspaper.

Ruling on Merck diabetes drug shows domestic firms not favored in India courts

Dilip Shah, secretary-general of the Indian Pharmaceutical Alliance, said this week's decision by the Delhi High Court against homegrown Glenmark Pharmaceuticals showed "due process was followed" and that Indian companies could not count on Indian courts for special treatment, according to a report in the Wall Street Journal.

Biologic drug patent differences stall TPP agreement at Atlanta talks

Officials from the U.S., Japan and 10 other Asia Pacific-rim countries remain stalemated over an agreement for the Trans Pacific Partnership currently being negotiated in Atlanta with the length of patent protection for biologic drugs a key stumbling block, the Japan News said.

Hikma gets large U.S. plant in Boehringer Ingelheim generics deal

Last year when Hikma bought Boehringer Ingelheim's Ben Venue injectable business, it decided not to reopen its long-troubled Bedford, OH, plant. But with a $2.65 billion deal announced today for Boehringer's Roxane generics business, it gets a U.S. manufacturing plant that it says it likes the looks of.

Sawai Pharma ramps up manufacturing in response to Japan's call for more generics

In May, the Japanese government said it would raise its target for the use of generics in public reimbursement to 80% or 90% by 2017--even as it lags an earlier target of 60% this year. That set Japan's Sawai Pharmaceutical into high gear, with the Nikkei Asian Review reporting plans to ramp up generic drug manufacturing capacity by 80% to 18 billion tablets annually by fiscal 2020.

Lupin walks the talk, buys Russian generics maker Biocom

Lupin Pharmaceuticals has made no secret of its intention to grow through acquisitions at home and abroad and last week announced it would make a major buy of Russian generic drug maker ZAO Biocom, placing it in a turbulent but fast-growing market.

Japan aims for high-end drug-device innovation and generics, but will it work?

Japan has ramped up spending on healthcare as part of a broader effort by the government to spur innovation and revive economic fortunes for drug and device makers while at the same time trying to tame costs for reimbursement and hiking sales taxes.

FTC says Teva settlement means pay-for-delay ends, maybe

Teva Pharmaceuticals and the U.S. Federal Trade Commission reached a $1.2 billion settlement that could mean the end of pay-for-delay deals, or not. Asia generics makers selling in the United States are likely to be affected.

Japan eyes higher target for generics despite missing earlier aims

Although it has not even reached its goal of generics comprising 60% of drugs prescribed in Japan, the government is about to raise it to 80% or 90%, according to reports.